Because free PSA (fPSA) became a biomarker identification in 1991,[3] many studies have shown that PSA has a high sensitivity but a low specificity, which can result in unnecessary biopsies, especially in patients with benign disease, and cancers overlap when the tPSA is moderately elevated. This evidence concerns the gene KLK3 and cancer.